statistiche ricercatore

statistiche per SARTORE BIANCHI, ANDREA

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5111
NA - Nord America 4460
AS - Asia 4173
SA - Sud America 127
OC - Oceania 114
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 16
Totale 14061
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4215
CN - Cina 3031
GB - Regno Unito 2557
IT - Italia 1144
DE - Germania 258
JP - Giappone 231
CA - Canada 217
KR - Corea 212
SE - Svezia 163
ES - Italia 146
IN - India 137
FR - Francia 129
DK - Danimarca 102
AU - Australia 99
TR - Turchia 99
TW - Taiwan 94
NL - Olanda 86
BR - Brasile 83
HK - Hong Kong 73
VN - Vietnam 69
FI - Finlandia 63
IR - Iran 58
UA - Ucraina 56
RO - Romania 54
CH - Svizzera 49
GR - Grecia 45
RU - Federazione Russa 38
PL - Polonia 32
NO - Norvegia 31
IL - Israele 27
BE - Belgio 26
TH - Thailandia 25
PT - Portogallo 24
MX - Messico 22
MY - Malesia 22
CZ - Repubblica Ceca 20
IE - Irlanda 18
ID - Indonesia 17
AT - Austria 15
NZ - Nuova Zelanda 15
CO - Colombia 14
HU - Ungheria 14
AR - Argentina 12
SG - Singapore 12
JO - Giordania 11
DZ - Algeria 10
SA - Arabia Saudita 10
EG - Egitto 9
PK - Pakistan 9
SK - Slovacchia (Repubblica Slovacca) 9
TN - Tunisia 9
EU - Europa 8
SC - Seychelles 8
UZ - Uzbekistan 8
CL - Cile 7
MA - Marocco 7
PE - Perù 7
HR - Croazia 6
AP - ???statistics.table.value.countryCode.AP??? 5
GN - Guinea 5
RS - Serbia 5
SI - Slovenia 5
MK - Macedonia 4
PH - Filippine 4
ZA - Sudafrica 4
A1 - ???statistics.table.value.countryCode.A1??? 3
AE - Emirati Arabi Uniti 3
IM - Isola di Man 3
LB - Libano 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BD - Bangladesh 2
BG - Bulgaria 2
BJ - Benin 2
CR - Costa Rica 2
CY - Cipro 2
EC - Ecuador 2
GT - Guatemala 2
IQ - Iraq 2
KE - Kenya 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
MT - Malta 2
SD - Sudan 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GI - Gibilterra 1
KW - Kuwait 1
LK - Sri Lanka 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
UY - Uruguay 1
Totale 14061
Salva come PNG Salva come JPEG
Città #
Southend 2205
Hangzhou 1005
Fairfield 474
Beijing 458
Milan 448
Redwood City 362
Seattle 360
Houston 309
Wilmington 291
Woodbridge 242
Cambridge 212
Shanghai 191
Ashburn 190
Nanjing 183
Dearborn 168
Guangzhou 157
Ottawa 148
Ann Arbor 141
Jinan 92
Tokyo 78
Shenyang 74
Taipei 60
Central District 58
Changsha 54
Torino 53
Istanbul 52
Hebei 50
Wuhan 50
Seoul 47
Chengdu 42
Dong Ket 42
Nanchang 39
Redmond 39
New York 36
Zhengzhou 35
Barcelona 33
Tianjin 33
Hefei 29
Rome 29
Falls Church 27
Jiaxing 25
San Diego 24
Phoenix 22
London 21
Rochester 21
Fremont 20
Newbury Park 20
Berlin 19
Fuzhou 19
Grafing 19
Silver Spring 19
Amsterdam 18
Duncan 18
Boston 17
Ningbo 17
Oslo 16
Uppsala 16
Kunming 15
Lanzhou 15
Taiyuan 15
Seongnam 14
Haikou 13
Jakarta 13
Madrid 13
Manchester 13
Bologna 12
Taizhou 12
Andover 11
Mountain View 11
Xian 11
Chongqing 10
Harbin 10
Madison 10
Baotou 9
Changchun 9
Chicago 9
Cluj-napoca 9
Heidelberg 9
Mumbai 9
Munich 9
New Delhi 9
Salt Lake City 9
Serio 9
Toronto 9
Utrecht 9
Athens 8
Birmingham 8
Brooklyn 8
Edinburgh 8
Lima 8
Mahé 8
Melbourne 8
Montréal 8
Moscow 8
Nijmegen 8
Norwalk 8
Nutley 8
Oxford 8
Padova 8
Plymouth 8
Totale 9353
Salva come PNG Salva come JPEG
Nome #
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer 2270
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 915
Liquid biopsy for rectal cancer: a systematic review 908
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies 496
Early-onset colorectal cancer in young individuals 448
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer 323
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 320
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition 292
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1) 292
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy 279
Third- or Later-line Therapy for Metastatic Colorectal Cancer : Reviewing Best Practice 268
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy 250
Challenging chemoresistant metastatic colorectal cancer: Therapeutic strategies from the clinic and from the laboratory 247
Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy 241
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer 234
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 223
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 167
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer : a retrospective consortium analysis 158
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 152
The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer 144
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 140
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience 137
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 131
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 128
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 126
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin 119
Detection of circulating tumor DNA in early- and late-stage human malignancies 115
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer 112
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 111
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in kras-mutant metastatic colorectal cancer 108
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 108
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma 106
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 104
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib 98
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers 97
The right chance for temozolomide in metastatic colorectal cancer? 95
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 92
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer 91
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies 88
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types 81
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 76
Adaptive mutability of colorectal cancers in response to targeted therapies 76
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer 73
Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast 73
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial 73
Central Nervous System as Possible Site of Relapse in ERBB2-PositiveMetastatic Colorectal Cancer:Long-term Results of TreatmentWith Trastuzumab and Lapatinib 72
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review 69
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 67
Assessment of a HER2 scoring system for colorectal cancer : results from a validation study 65
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer 65
Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer 64
Clonal evolution andKRAS-METcoamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 64
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma 63
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 62
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 62
Regorafenib in metastatic colorectal cancer 58
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer 58
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 58
A molecularly annotated platform of patient- derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 57
TRKA expression and NTRK1 gene copy number across solid tumours 57
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer 56
Acquired resistance to EGFR-targeted therapies incolorectal cancer 54
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System 54
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 54
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge : Single Institution Series and Systematic Review Study 54
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 54
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 54
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study 53
Cetuximab for treatment of metastatic colorectal cancer 53
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 50
Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases 50
The genomic landscape of response to EGFR blockade in colorectal cancer 49
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab 49
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection : a Systematic Review and Meta-Analysis 49
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer 48
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 48
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 48
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study 47
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer 47
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients 47
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 46
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression 46
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer 45
Rationale and clinical results of multi-target treatments in oncology 45
Translational challenges from the 2014 Gastrointestinal Cancers Symposium : Toward a true tailored therapy through effective research 44
EGFR FISH in colorectal cancer: what is the current reality? 44
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 44
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 44
Regorafenib for metastatic colorectal cancer 43
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 43
Gemcitabine and Oxaliplatin in the Treatment of Patients with Immunotherapy-Resistant Advanced Renal Cell Carcinoma: Final Results of a Single-Institution Phase II Study 43
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 42
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab 42
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 42
Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature 42
Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution 40
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy 40
Is codon 13 KRAS mutation biologically different from codon 12 mutation 40
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies 40
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 40
Totale 13999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/2017370 0000 00 1621 94620330
2017/20181887 9810710270 69192 101197 173315278185
2018/20192546 446252231188 125164 18793 199164272225
2019/20204057 336204159298 333415 374296 560423297362
2020/20213918 371359297250 410299 238296 442453242261
2021/20221927 334254271324 322196 2260 0000
Totale 15154
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2022